As of 2025-07-08, the EV/EBITDA ratio of Apellis Pharmaceuticals Inc (APLS) is -12.26. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Apellis's latest enterprise value is 2,284.37 mil USD. Apellis's TTM EBITDA according to its financial statements is -186.25 mil USD. Dividing these 2 quantities gives us the above Apellis EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 11.7x - 13.7x | 13.0x |
| Forward P/E multiples | 18.7x - 33.4x | 25.0x |
| Fair Price | (28.41) - (21.00) | (28.95) |
| Upside | -263.1% - -220.5% | -266.2% |
| Date | EV/EBITDA |
| 2025-07-07 | -12.26 |
| 2025-07-03 | -12.83 |
| 2025-07-02 | -12.53 |
| 2025-07-01 | -12.57 |
| 2025-06-30 | -12.19 |
| 2025-06-27 | -12.27 |
| 2025-06-26 | -12.93 |
| 2025-06-25 | -12.92 |
| 2025-06-24 | -13.07 |
| 2025-06-23 | -12.40 |
| 2025-06-20 | -12.45 |
| 2025-06-18 | -12.49 |
| 2025-06-17 | -12.49 |
| 2025-06-16 | -12.86 |
| 2025-06-13 | -13.22 |
| 2025-06-12 | -13.51 |
| 2025-06-11 | -13.51 |
| 2025-06-10 | -13.72 |
| 2025-06-09 | -13.59 |
| 2025-06-06 | -13.52 |
| 2025-06-05 | -13.40 |
| 2025-06-04 | -13.00 |
| 2025-06-03 | -13.21 |
| 2025-06-02 | -13.43 |
| 2025-05-30 | -11.93 |
| 2025-05-29 | -12.26 |
| 2025-05-28 | -11.85 |
| 2025-05-27 | -11.91 |
| 2025-05-23 | -12.28 |
| 2025-05-22 | -12.51 |
| 2025-05-21 | -12.26 |
| 2025-05-20 | -13.00 |
| 2025-05-19 | -12.43 |
| 2025-05-16 | -12.29 |
| 2025-05-15 | -11.55 |
| 2025-05-14 | -11.78 |
| 2025-05-13 | -12.17 |
| 2025-05-12 | -12.33 |
| 2025-05-09 | -12.18 |
| 2025-05-08 | -12.53 |
| 2025-05-07 | -12.65 |
| 2025-05-06 | -13.41 |
| 2025-05-05 | -13.99 |
| 2025-05-02 | -14.24 |
| 2025-05-01 | -14.06 |
| 2025-04-30 | -13.47 |
| 2025-04-29 | -12.80 |
| 2025-04-28 | -12.63 |
| 2025-04-25 | -12.31 |
| 2025-04-24 | -12.35 |